V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting

May 17, 1998

LOS ANGELES --- Noted breast cancer drug researcher V. Craig Jordan will present the findings of one of Eli Lilly Company's studies of the drug raloxifene (EvistaR) at the American Society for Clinical Oncology meeting in Los Angeles on Sunday, May 17.

More than 10,000 postmenopausal women age 41 to 80 taking EvistaR for approximately 32 months had a 54 percent reduction in the incidence of newly diagnosed breast cancers when compared to their counterparts who were taking placebo.

Raloxifene is an antiestrogen, a drug that works by blocking the estrogen receptors in the breast, thereby preventing the hormone estrogen from contributing to the growth of cancer. Jordan and other breast cancer researchers believe that the estrogenic properties of drugs such as raloxifene may also be targeted to prevent osteoporosis and heart attacks in postmenopausal women.

Jordan is a professor of cancer pharmacology at Northwestern University Medical School and director of the Breast Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

He was the first scientist to note that tamoxifen, a drug originally developed for birth control, seemed to prevent the growth of mammary tumors in rodents. Tamoxifen subsequently was found to increase the survival of breast cancer patients and also to prevent the development of second breast cancers.

In 1993 Jordan was selected to receive the prestigious Cameron Prize from the University of Edinburgh. He has also received major scientific awards from the American Association for Cancer Research, the American Society for Pharmacology and Experimental Therapeutics and the Sir John Gaddum Award at Cambridge University, England, from the British Pharmacological Society for his contributions to pharmacology.

In addition, he received the American-Italian Award for Scientific Excellence in Medicine for his breast cancer prevention research and the Block Award for Distinguished Achievement in Cancer Research from The Ohio State University. Most recently, he was named the Sixth Laureate of the Cino del Duca Award for Oncology in Paris. He also is a fellow of the Royal Society of Chemistry and the American Institute of Chemists.

Jordan received a bachelor of science degree and a Ph.D. from the department of pharmacology from Leeds University Medical School, England. Before joining the Northwestern University faculty in 1993, he was a professor of human oncology and pharmacology and director of the breast cancer program at the University of Wisconsin Comprehensive Cancer Center, Madison.

(Editor's note: V. Craig Jordan can be reached from May 15 through 19 at the American Society for Clinical Oncology meeting at the Westin Bonaventure Hotel, Los Angeles, (213) 624-1000, or through Stacey Isaacs at Cohn & Wolfe, New York, at (212) 598-3636.)

Northwestern News on the World Wide Web: http://www.nwu.edu/univ-relations/media/

CONTACT: Elizabeth Crown at (312) 503-8928 or e-mail at e-crown@nwu.edu
Broadcast Media Contact: Stephanie Clemson at (847) 491-4888 or s-clemson@nwu.edu

Northwestern University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.